Copyright: ©Author(s) 2026.
World J Hepatol. Oct 27, 2026; 18(10): 125505
Published online Oct 27, 2026. doi: 10.4254/wjh.125505
Published online Oct 27, 2026. doi: 10.4254/wjh.125505
Table 1 Basic sociodemographic characteristics and comorbidities of study participants (n = 67)
| Characteristic | n (%) | |
| Median age and range in years | 66 (37-89) | |
| Gender | Male | 40 (59.7) |
| Female | 27 (40.3) | |
| Duration of diabetes mellitus type 2 (T2DM) | < 5 years | 40 (59.7) |
| 5-10 years | 16 (23.9) | |
| 11-15 years | 5 (7.5) | |
| > 15 years | 6 (9.0) | |
| Comorbidities (other than T2DM) | Hypertension | 53 (79) |
| Kidney disease | 9 (13.4) | |
| Hyperlipidemia | 42 (62.7) | |
| Hypothyroidism | 3 (4.5) | |
| Hyperthyroidism | 1 (1.5) | |
| Depression | 4 (6.0) | |
| Anxiety | 2 (3.0) | |
| Liver disease | 6 (9.0) | |
| Gallbladder and bile duct disease | 5 (7.5) | |
| Other comorbidities | 14 (20.9) | |
- Citation: Khaznadar F, Bojanić K, Khaznadar O, Jurić A, Hefer M, Kralik K, Petrović A, Hrženjak A, Lončar A, Steiner J, Smolić M, Smolić R. Changes in lipid biomarkers, liver stiffness and steatosis following sodium-glucose cotransporter two inhibitor therapy in type two diabetes. World J Hepatol 2026; 18(10): 125505
- URL: https://www.wjgnet.com/1948-5182/full/v18/i10/125505.htm
- DOI: https://dx.doi.org/10.4254/wjh.125505